All In Biotech

Drug Trial Radar · NCT04357366

suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)

suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial

Last checked: Nov 20, 2026Latest source record: Jul 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,000

Actual

Start

Apr 15, 2020

Primary completion

Jan 29, 2022

Study completion Apr 15, 2022

Sponsor

Lead sponsor
Hellenic Institute for the Study of SepsisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In the SAVE study patients with lower respiratory tract infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at high risk for progression to serious respiratory failure will be detected using the suPAR biomarker. They will begin early treatment with anakinra in the effort to prevent progression in serious respiratory failure.

Conditions

  • COVID-19
  • Virus Diseases
  • Corona Virus Infection
  • Lower Respiratory Tract Infection Viral

Interventions

  • AnakinraDrug

    Treatment with 100mg Anakinra subcutaneously (sc) once daily for ten days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The ratio of patients who will develop serious respiratory failure (SRF)Time frame: Visit study day 14

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • 2nd Department of Internal Medicine, University General Hospital of Alexandroupolis

    Alexandroupoli, Greece

  • Department of Internal Medicine, I PAMMAKARISTOS Hospital

    Athens, Greece

  • 1st Department of InternalMedicine, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S.

    Athens, Greece

  • 1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS

    Athens, Greece

  • 1st University Department of Internal Medicine, General Hospital of Athens LAIKO

    Athens, Greece

  • 1st University Departmentof Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseasesof Athens

    Athens, Greece

  • 2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens

    Athens, Greece

  • 3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA

    Athens, Greece

  • Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA

    Athens, Greece

  • Department of Clinical Therapeutics, ALEXANDRA General Hospital of Athens

    Athens, Greece

  • 1st Department of Internal Medicine Amalia Fleming General Hospital

    Athens, Greece

  • 1st Department of Internal Medicine, General Hospital of Eleusis THRIASIO

    Athens, Greece

  • 1st Department of Internal Medicine, General Hospital of Nea Ionia CONSTANTOPOULIO-PATISION

    Athens, Greece

  • 1st Department of Internal Medicine, General Hospital of Voula ASKLEPIEIO

    Athens, Greece

  • 2nd Department of Internal Medicine, 251 Air Force General Hospital

    Athens, Greece

  • 2nd Department of Internal Medicine, General Hospital of Eleusis THRIASIO

    Athens, Greece

  • 3rd Department of Internal Medicine, General Hospital of Athens KORGIALENEIO-BENAKEIO E.E.S.

    Athens, Greece

  • 5th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens

    Athens, Greece

  • Department of Internal Medicine, General Hospital of Athens ELPIS

    Athens, Greece

  • Department of Infectious Diseases, General Hospital of Kerkira

    Corfu, Greece

  • 1st Department of Internal Medicine, General University Hospital of Ioannina

    Ioannina, Greece

  • Department of Internal Medicine, General Hospital of Katerini

    Katerini, Greece

  • Department of Internal Medicine, University General Hospital of Larissa

    Larissa, Greece

  • Department of Internal Medicine, General Hospital of Larisa KOUTLIMBANEIO & ΤΡΙΑΝΤΑFΥLLΕΙΟ

    Larissa, Greece

  • Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA

    Pátrai, Greece

  • 2nd Department of Internal Medicine, General Hospital of Piraeus TZANEIO

    Piraeus, Greece

  • 1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki

    Thessaloniki, Greece

  • COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING

    Marousi, Athens, Greece

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.